What's Happening?
Eli Lilly and Company has announced the acquisition of Kelonia Therapeutics, a gene delivery biotech, in a deal valued at up to $7 billion. This acquisition includes Kelonia's Phase 1 lentiviral in vivo CAR-T therapy, KLN-1010, and its innovative in vivo gene delivery and integration
technology, iGPS. The iGPS platform utilizes lentiviral-based particles to deliver T-cells, allowing the patient's body to generate its own CAR T therapies, potentially eliminating the need for complex manufacturing processes and pre-treatment chemotherapy. This strategic move is expected to bolster Lilly's capabilities in genetic medicines and expand its oncology and immunology franchises. The acquisition follows Lilly's earlier $2.4 billion purchase of Orna Therapeutics, marking its second major investment in the CAR T space this year.
Why It's Important?
The acquisition of Kelonia Therapeutics by Eli Lilly is significant as it positions the company to enhance its presence in the rapidly evolving field of genetic medicines, particularly in oncology. The iGPS technology could revolutionize CAR T therapy by simplifying the production process and reducing costs, which may lead to broader accessibility and application in treating various conditions. This move also reflects Lilly's strategic focus on expanding beyond traditional small molecules and antibodies, aiming for durable growth in oncology. However, the in vivo CAR T approach remains unproven and carries risks, with competition from major players like Gilead Sciences, AbbVie, and Bristol Myers Squibb. Success in this area could provide Lilly with a competitive edge and significant market share in the oncology sector.
What's Next?
The deal is expected to close in the second half of 2026, with Lilly paying $3.25 billion upfront and additional payments contingent on achieving specific milestones. As the acquisition progresses, Lilly will likely focus on integrating Kelonia's technology into its existing operations and exploring its application to other conditions. The company will also need to navigate the competitive landscape and address the challenges associated with in vivo CAR T development. Stakeholders, including investors and industry analysts, will be closely monitoring Lilly's ability to leverage this acquisition to drive innovation and growth in its oncology and immunology portfolios.
